中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2015年
1期
25-28
,共4页
胰岛素%投药,鼻内%阿尔茨海默病%认知障碍
胰島素%投藥,鼻內%阿爾茨海默病%認知障礙
이도소%투약,비내%아이자해묵병%인지장애
Insulin%Administration,intranasal%Alzheimer disease%Cognition disorders
目的 探讨鼻内滴入不同剂量胰岛素对阿尔茨海默病(AD)患者认知功能障碍的影响.方法 将63例AD患者按照就诊顺序分为三组:胰岛素1组(21例)、胰岛素2组(21例)和安慰剂组(21例),胰岛素1组给予每次鼻内滴入20U胰岛素,每日2次;胰岛素2组给予每次鼻内滴入40U胰岛素,每日2次;安慰剂组给予鼻内滴入0.9％氯化钠,每日2次.使用简易精神状态评价量表(MMSE)及Rivermead记忆测验第2版(RBMTⅡ)评价鼻内滴入不同剂量胰岛素后3个月及6个月患者认知功能的改善程度.结果 治疗后3个月,胰岛素1组和胰岛素2组MMSE评分和RBMTⅡ评分得到明显改善[MMSE评分:(21.8±3.2)分比(20.2±2.3)分,(21.6±3.5)分比(20.7±2.8)分;RBMTⅡ评分:(19.2±2.0)分比(17.2±1.9)分,(18.1±2.0)分比(16.5±1.9)分],差异有统计学意义(P＜ 0.05或＜0.01),安慰剂组MMSE评分和RBMTⅡ评分明显恶化[(18.9±3.8)分比(20.9±2.5)分;(15.2±2.1)分比(16.1±2.0)分],差异有统计学意义(P＜0.05).治疗后6个月,胰岛素1组和胰岛素2组MMSE评分和RBMTⅡ评分明显优于安慰剂组[MMSE评分:(22.5±3.3),(22.7±3.1)分比(17.9±4.5)分;RBMTⅡ评分:(20.5±2.0),(19.8±1.9)分比(14.7±2.0)分],差异有统计学意义(P＜0.01).结论 鼻内滴入胰岛素可以改善AD患者的认知功能.
目的 探討鼻內滴入不同劑量胰島素對阿爾茨海默病(AD)患者認知功能障礙的影響.方法 將63例AD患者按照就診順序分為三組:胰島素1組(21例)、胰島素2組(21例)和安慰劑組(21例),胰島素1組給予每次鼻內滴入20U胰島素,每日2次;胰島素2組給予每次鼻內滴入40U胰島素,每日2次;安慰劑組給予鼻內滴入0.9％氯化鈉,每日2次.使用簡易精神狀態評價量錶(MMSE)及Rivermead記憶測驗第2版(RBMTⅡ)評價鼻內滴入不同劑量胰島素後3箇月及6箇月患者認知功能的改善程度.結果 治療後3箇月,胰島素1組和胰島素2組MMSE評分和RBMTⅡ評分得到明顯改善[MMSE評分:(21.8±3.2)分比(20.2±2.3)分,(21.6±3.5)分比(20.7±2.8)分;RBMTⅡ評分:(19.2±2.0)分比(17.2±1.9)分,(18.1±2.0)分比(16.5±1.9)分],差異有統計學意義(P＜ 0.05或＜0.01),安慰劑組MMSE評分和RBMTⅡ評分明顯噁化[(18.9±3.8)分比(20.9±2.5)分;(15.2±2.1)分比(16.1±2.0)分],差異有統計學意義(P＜0.05).治療後6箇月,胰島素1組和胰島素2組MMSE評分和RBMTⅡ評分明顯優于安慰劑組[MMSE評分:(22.5±3.3),(22.7±3.1)分比(17.9±4.5)分;RBMTⅡ評分:(20.5±2.0),(19.8±1.9)分比(14.7±2.0)分],差異有統計學意義(P＜0.01).結論 鼻內滴入胰島素可以改善AD患者的認知功能.
목적 탐토비내적입불동제량이도소대아이자해묵병(AD)환자인지공능장애적영향.방법 장63례AD환자안조취진순서분위삼조:이도소1조(21례)、이도소2조(21례)화안위제조(21례),이도소1조급여매차비내적입20U이도소,매일2차;이도소2조급여매차비내적입40U이도소,매일2차;안위제조급여비내적입0.9％록화납,매일2차.사용간역정신상태평개량표(MMSE)급Rivermead기억측험제2판(RBMTⅡ)평개비내적입불동제량이도소후3개월급6개월환자인지공능적개선정도.결과 치료후3개월,이도소1조화이도소2조MMSE평분화RBMTⅡ평분득도명현개선[MMSE평분:(21.8±3.2)분비(20.2±2.3)분,(21.6±3.5)분비(20.7±2.8)분;RBMTⅡ평분:(19.2±2.0)분비(17.2±1.9)분,(18.1±2.0)분비(16.5±1.9)분],차이유통계학의의(P＜ 0.05혹＜0.01),안위제조MMSE평분화RBMTⅡ평분명현악화[(18.9±3.8)분비(20.9±2.5)분;(15.2±2.1)분비(16.1±2.0)분],차이유통계학의의(P＜0.05).치료후6개월,이도소1조화이도소2조MMSE평분화RBMTⅡ평분명현우우안위제조[MMSE평분:(22.5±3.3),(22.7±3.1)분비(17.9±4.5)분;RBMTⅡ평분:(20.5±2.0),(19.8±1.9)분비(14.7±2.0)분],차이유통계학의의(P＜0.01).결론 비내적입이도소가이개선AD환자적인지공능.
Objective To investigate the effect of intranasal instillation of insulin with different doses on cognitive function in patients with Alzheimer disease (AD).Methods Sixty-three AD patients were collectcd.According to the order of doctor's office visiting,they were divided into insulin 1 group (21 cases,intranasal instillation of insulin 20 U,2 times per day),insulin 2 group (21 cases,intranasal instillation of insulin 40 U,2 times per day) and placebo group (21 cases,intranasal instillation of physiological saline,2 times per day).Mini-mental state examination scale (MMSE) and Rivermead behavioural memory test second edition (RBMT Ⅱ) were used to evaluate the improvement of cognitive function after 3 months and 6 months.Results Before treatment,the scores of MMSE and RBMT Ⅱ in insulin 1 group were (20.2 ± 2.3) and (17.2 ± 1.9) scores,in insulin 2 group were (20.7 ± 2.8) and (16.5 ± 1.9) scores.After treatment for 3 months,the scores of MMSE and RBMT Ⅱ in insulin 1 group were (21.8 ± 3.2) and (19.2 ± 2.0) scores,in insulin 2 group were (21.6 ± 3.5) and (18.1 ± 2.0) scores.The scores of MMSE and RBMT Ⅱ in insulin 1 group and insulin 2 group significantly improved compared with those before treatment (P ＜ 0.05 or ＜ 0.01).But the scores of MMSE and RBMT Ⅱ in placebo group were significantly aggravated,(18.9 ± 3.8) scores vs.(20.9 ± 2.5) scores,(15.2 ± 2.1) scores vs.(16.1 ± 2.0) scores,P ＜ 0.05.After treatment for 6 months,the scores of MMSE and RBMT Ⅱ in insulin 1 group were (22.5 ± 3.3) and (20.5 ± 2.0) scores,in insulin 2 group were (22.7 ± 3.1) and(19.8 ± 1.9) scores,and in placebo group were (17.9 ± 4.5) and(14.7 ± 2.0) scores.The scores of MMSE and RBMT Ⅱ in insulin 1 group and insulin 2 group were significantly better than those in placebo group (P ＜ 0.01).Conclusion Intranasal instillation of insulin can improve cognitive disorders in patients with AD.
